Small molecule · Inhibitor of ubiquitin specific protease 1 (USP1) · developed by Exelixis
ISM3091 (XL309) is an orally bioavailable small molecule that binds and inhibits the deubiquitinating enzyme USP1, blocking its deubiquitinating activity. USP1 regulates the Fanconi anemia complex and translesion synthesis in DNA repair. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05932862 | Phase 1 | Advanced Solid Tumor | Active not recruiting | EXEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.
See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EXEL catalysts and pipeline →